Genomics Core

项目摘要/摘要 基因组学核心的目的是提供仪器、计算基础设施、技术和 分析专门知识和指导，以便广泛启用和加强囊状细胞基因组分析的使用 纤维化(CF)研究。在其他研究重点领域中，基因组学核心特别强调 了解慢性萎缩性胃炎患者的宿主-微生物相互作用。核心的目标是：1)提供 测序和计算资源以研究CF肠道中的微生物群落，2)提供 推进相关病原体研究的尖端测序和计算资源 3)为了解基因表达和分子水平提供高级服务 与CF疾病状态相关的人类细胞的生理学，以及4)开发用于 纤维素酶微生物学的基因组水平分析。 这些目标将通过为威斯康星大学的CF研究人员提供咨询、生产和分析来实现 与以下域相关的服务： 基因组学方法和实验设计咨询。 二、数据分析、数据管理和数据共享服务。 三、细菌全基因组测序。 四、元基因组和16S rRNA微生物组数据的生成和分析。 V.转录组测序(RNA-Seq)和靶向基因表达分析(qRT-PCR)。 六、数字液滴聚合酶链式反应(DPCR)检测肠道微生物。 七.新的测序技术创新。 除了在不同的时间点和在不同的疾病状态下定义肠道的微生物组之外 患有慢性萎缩性胃炎的个人，核心将在推动项目方面发挥主要作用，以定义 胃肠道(GI)和呼吸道在CF患者整个生命周期中的变化，并了解 高效CFTR调节剂的应用如何改变细胞的组成和代谢功能 微生物群及其与宿主细胞的界面。

PROJECT SUMMARY/ABSTRACT The purpose of the Genomics Core is to provide instrumentation, computational infrastructure, technical and analytic expertise, and guidance in order to broadly enable and to enhance the use of genomic analysis in Cystic Fibrosis (CF) research. Among other areas of research focus, the Genomics Core places a special emphasis in understanding host-microbe interactions in individuals with CF. The Aims of the Core are to: 1) Provide sequencing and computational resources to study microbial communities in the CF gut, 2) Provide cutting-edge sequencing and computational resources that advance research on pathogens associated with CF disease states, 3) Provide advanced services to understand gene expression and molecular physiology of human cells that are relevant to CF disease states, and 4) Develop novel technologies for the genome-scale analysis of CF microbiology. These aims will be fulfilled by providing UW CF researchers with consultative, production, and analytical services relevant to the following domains: i. Consultation on genomic methods and experimental design. ii. Data Analysis, Data Management, and Data Sharing Services. iii. Bacterial whole genome sequencing. iv. Metagenomic and 16S rRNA Microbiome data generation and Analysis. v. Transcriptome sequencing (RNA-Seq) and targeted gene expression analysis (qRT-PCR). vi. Gut microbe quantitation by Digital Droplet PCR (dPCR). vii. New sequencing technology innovation. In addition to defining the microbiome of the gut at various timepoints and in various disease states of individuals with CF, the Core will play a primary role in driving projects to define how the microbiomes of the gastrointestinal (GI) and respiratory tracts change across the full lifespan of patients with CF, and to understand how the administration of highly effective CFTR modulators changes the composition and metabolic functions of the microbiome and its interface with host cells.